International Review of Ophthalmology

Previous Articles     Next Articles

The application of anti-VEGF antibody bevacizumab in glaucoma filtration surgery

ZUO Lei1, XU Xun2.   

  1. 1. Branch of Shanghai First People’s Hospital, Shanghai 200081, China; 2. Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai 200080, China
  • Received:2017-06-26 Online:2017-10-22 Published:2017-10-26
  • Contact: XU Xun, Email: drxuxun@sjtu. edu.cn
  • Supported by:
     Key Research Project of Shanghai City Health and Family Planning Commission(201640027)

Abstract:

Angiogenesis may pose a clinical challenge in glaucoma during the wound healing phase after glaucoma filtration surgery (GFS). In recent years, anti-VEGF antibody bevacizumab (BVZ) has been used in GFS in order to improve the operation success rate safely, such as primary open angle glaucoma, pigmentary glaucoma, exfoliation glaucoma,chronic angle closure glaucoma, neovascular glaucoma, and the filtering surgery after failure of glaucoma surgery.The mode of application include  topical, subconjunctival injection, intracameral injection, intravitreal injection, combination therapy, etc.(Int Rev Ophthalmol,  2017,  41:   323-327)